-
Mashup Score: 11How the landscape of treating CRPC has evolved with the introduction of targeted treatment - 2 month(s) ago
Rob Jones, MD, PhD, The University of Glasgow, Glasgow, UK, discusses the evolving landscape of treating castration-resistant prostate cancer (CRPC) with the introduction of targeted treatments. In the past five years, the nature of CRPC has shifted, with patients often having already received androgen receptor-targeted therapies (e.g., enzalutamide, abiraterone) in the hormone-sensitive state. Modern-day CRPC encompasses resistance not just to castration but also to androgen receptor-targeted therapies. This presents challenges in therapeutic options, especially as patients may progress rapidly. Prof. Jones explores the limitations of sequential therapies and highlights emerging options, such as PARP inhibitors (e.g., olaparib) and combination trials with androgen receptor therapies. The complexity of these treatments and their efficacy in patients with specific mutations, particularly BRCA or HRD, necessitates further research to optimize CRPC management. This interview took place at
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11How the landscape of treating CRPC has evolved with the introduction of targeted treatment - 4 month(s) ago
Rob Jones, MD, PhD, The University of Glasgow, Glasgow, UK, discusses the evolving landscape of treating castration-resistant prostate cancer (CRPC) with the introduction of targeted treatments. In the past five years, the nature of CRPC has shifted, with patients often having already received androgen receptor-targeted therapies (e.g., enzalutamide, abiraterone) in the hormone-sensitive state. Modern-day CRPC encompasses resistance not just to castration but also to androgen receptor-targeted therapies. This presents challenges in therapeutic options, especially as patients may progress rapidly. Prof. Jones explores the limitations of sequential therapies and highlights emerging options, such as PARP inhibitors (e.g., olaparib) and combination trials with androgen receptor therapies. The complexity of these treatments and their efficacy in patients with specific mutations, particularly BRCA or HRD, necessitates further research to optimize CRPC management. This interview took place at
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
🎥Rob Jones, MD, PhD, of @UofGlasgow discusses the evolving landscape of treating CRPC with targeted therapies, addressing challenges in the era of resistance to androgen receptor-targeted treatments: ➡️https://t.co/2ehzDuZ3yx⬅️ #PROSCA23 #PCSM